JOURNEY AS AN ORTHOPAEDIC SURGEON, RESEARCHER, SURGICAL SITE INFECTION CONTROL & BONE LOSS EXPERT Associate Professor Kevin Tetsworth, Orthopaedic Surgeon
As an orthopaedic surgeon, Associate Professor Kevin Tetsworth, is widely recognised for his expertise in managing orthopaedic infections, chronic osteomyelitis, limb salvage, and reconstruction. He holds clinical appointments at the Royal Brisbane and Women’s Hospital, the Wesley Hospital in Brisbane, Macquarie University in Sydney at the Limb Reconstruction Centre.
His credentials encompass a fellowship in the American Academy, a fellowship in the Royal College in Australia, and membership in the Australian Orthopaedic Association and the International Orthopaedic Trauma Association. Associate Professor Tetsworth’s clinical focus revolves around the comprehensive management of orthopaedic infections, segmental bone defects, high-energy trauma, limb salvage and reconstruction, deformity correction, limb lengthening, and prosthetic joint infections.
In tandem with his clinical practice, Associate Professor Tetsworth is deeply engaged in orthopaedic research, with a keen interest in infection management, infection control, limb salvage, bone defect reconstruction, biomarker development for infection, bone growth hormone delivery, and the use of 3D printed models for reconstructing segmental bone defects.
His professional journey has been profoundly shaped by training under esteemed mentors like Professor Dror Paley and Dr George Cierny in the United States. This formative training has equipped him with a high level of expertise in addressing complex orthopaedic conditions, particularly those related to bone loss and infection. Having practiced in the United States, notably at the University of Maryland and the shock trauma hospital in Baltimore, Associate Professor Tetsworth relocated to Australia in 2000 and has since played a pivotal role in advancing orthopaedic surgery at the Royal Brisbane Hospital.
Associate Professor Tetsworth’s unwavering commitment to advancing orthopaedic knowledge and his exceptional proficiency in managing challenging orthopaedic conditions have earned him widespread recognition within the field.
In this Australian Health Journal interview, Assoc Professor Tetsworth talks about his clinical and research career journey and gives advice for those in medicine considering a career in orthopaedic surgery,
Assoc Prof Tetsworth concludes with a discussion on ways infection control is handled in preoperative, intraoperative and post operatively for orthopaedic surgeries.
He discusses the techniques started in the 19th century with understanding of hand hygiene, surgical instruments being sterilised and discovery of antibiotics in the 20th century, to present day practises of patient modifiable factors such as prescreening patients, lifestyle adjustments such as BMI or weight management, checking HbA1c levels for those who are diabetic and use of triclosan coated sutures in wound dressing in the early post operative period.
-
Investments to address health inequities in Prostate Cancer Care
Income, education, geographical location, and discrimination based on ethnicity, race, gender and sexual orientation, are only a fraction of factors that can negatively affect a person’s quality of cancer care. This is defined as the “equity gap” and it’s costing people their lives.
Timed to coincide with World Cancer Day 4th February 2025, Movember announced prostate cancer investment of $5.5 million. Eighteen grants (16 proposals and 2 community development grants) are slated to directly tackle inequities in prostate cancer care. The funding will be over three years with the grants spread across five countries – six in Canada, five in the United Kingdom, three in Australia, three in the United States and one in Ireland – each having a specific focus population and care area.
-
Foundation outlines breast cancer research strategy
Australian Health Journal met with Associate Professor Cleola Anderiesz, CEO of the National Breast Cancer Foundation to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.
-
Targeted National Lung Cancer Screening Program commences in 2025
In February 2025, Australian Health Journal spoke with Mark Brooke, Chief Executive Officer of Lung Foundation Australia, at the 10th Australian Lung Cancer Conference in Adelaide, on the upcoming commencement of the National Lung Cancer Screening Program (NLCSP)
